5 completed, 5 unknown, 1 not yet recruiting, 1 recruiting. 12 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 5, Unknown 5, Not yet recruiting 1, Recruiting 1 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma selinexor - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 4 | Unknown | Chongqing University Cancer Hospital | 32 | 2023-02-28 | 2023-03-28 |
| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine - Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma | Phase 4 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 300 | 2022-05-25 | 2022-08-26 |
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit - Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 4 | Completed | Vanderbilt-Ingram Cancer Center | 25 | 2021-12-02 | 2025-03-27 |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Decitabine - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 60 | 2018-06-01 | 2018-09-14 |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (R)-CHOP regimen, (R)-CVP regimen - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2017-07-01 | 2018-05-01 |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma Apatinib - Relapsed and Refractory, Diffuse Large B Cell Lymphoma | Phase 4 | Completed | Zhengzhou University | 32 | 2017-01-01 | 2019-07-25 |
| Reduced Chemotherapy in Low Risk DLBCL Rituximab, Cyclophosphamide, Epirubicin - Diffuse Large B-cell Lymphoma | Phase 4 | Unknown | Ruijin Hospital | 290 | 2016-06-14 | 2022-12-05 |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin - Hodgkin Lymphoma | Phase 4 | Completed | Millennium Pharmaceuticals, Inc. | 60 | 2014-03-14 | 2021-04-09 |
| Treatment of Diffuse Large B Cell Lymphoma Yangzhengxiaoji capsule combined with CHOP regimen, CHOP regimen - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 120 | 2012-09-01 | 2015-12-30 |
| LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) R-CHOP, Highly active antiretroviral therapy, Central nervous system (CNS) prophylaxis - HIV Infections, Diffuse Large B Cell Lymphoma | Phase 4 | Completed | PETHEMA Foundation | 50 | 2006-10-01 | 2009-11-25 |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cyclophosphamide - Anemia, Graft Versus Host Disease | Phase 4 | Completed | University of Maryland, Baltimore | 45 | 1998-09-01 | 2019-10-17 |
Recurrence (3) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Lymphoma (2) · Anemia (1) · Blast Crisis (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1) · HIV Infections (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma, B-Cell (11) · Lymphoma, Non-Hodgkin (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma (10) · Disease Attributes (3) · Infections (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Virus Diseases (3)
Cyclophosphamide (4) · Rituximab (2) · Vincristine (2) · Antilymphocyte Serum (1) · Antiretroviral Therapy, Highly Active (1) · Blood Pressure (1) · Brentuximab Vedotin (1) · Carmustine (1) · Cytarabine (1) · Decitabine (1) · Dexamethasone (1) · Doxorubicin (1) · Epirubicin (1) · Etoposide (1) · Filgrastim (1)
Mingzhi Zhang (3) · Chongqing University Cancer Hospital (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Millennium Pharmaceuticals, Inc. (1) · PETHEMA Foundation (1) · Ruijin Hospital (1) · The First Hospital of Jilin University (1) · University of Maryland, Baltimore (1) · Vanderbilt-Ingram Cancer Center (1) · Zhengzhou University (1)
China (6) · Spain (2) · United States (2) · Czechia (1) · Germany (1) · Malaysia (1) · Poland (1) · Russia (1) · Thailand (1) · Turkey (Türkiye) (1)
Barry R. Meisenberg, MD (1) · Mingzhi Zhang (1) · Mingzhi Zhang, Dr (1) · Olalekan Oluwole, MD (1) · Oriol Albert, Dr (1) · Ribera Josep M, Dr (1) · Weili Zhao, MD, PhD (1)
PMID 16648042, PMID 19219604, PMID 20660832, PMID 23615461, PMID 23753028, PMID 25934708, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631, PMID 30881137, PMID 32158186, PMID 32487143, PMID 32589977, PMID 33148342, PMID 33202794, PMID 33764240, PMID 34222013, PMID 37403255, PMID 7477169